* PARKER-HANNIFIN - ‍FDA GIVEN ADDITIONAL CLEARANCE TO MARKET & SELL INDEGO EXOSKELETON FOR USE IN TREATMENT OF INDIVIDUALS WITH HEMIPLEGIA DUE TO STROKE​ Source text for Eikon: Further company coverage: